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Background: All-trans retinoic acid (ATRA) is currently being used to treat hematological malignancies, given the
ability to inhibit cell proliferation. This effect seems to be related to epigenetic changes of the TERT (Telomerase
Reverse Transcriptase) promoter. When hypomethylated, ATRA-inducible TERT repressors can bind the promoter,
repressing transcription of TERT, the rate-limiting component of telomerase. Ovarian carcinomas are heterogeneous
tumors characterized by several aberrantly methylated genes among which is TERT. We recently found a
hypomethylation of TERT promoter in about one third of serous carcinoma, the most lethal histotype. Our aim was
to investigate the potential role of ATRA as an anticancer drug in a sub-group of ovarian carcinoma where the TERT
promoter was hypomethylated.
Methods: The potential antiproliferative and cytotoxic effect of ATRA was investigated in seven serous ovarian
carcinoma and one teratocarcinoma cell lines and the results were compared to the methylation status of their
TERT promoter.
Results: The serous ovarian carcinoma cell line OVCAR3, harboring a hypomethylated TERT promoter, was the best
and fastest responder. PA1 and SKOV3, two cell lines with an intermediate methylated promoter, revealed a weaker
and delayed response. On the contrary, the other 5 cell lines with a highly methylated promoter did not respond
to ATRA, indicative of ATRA-resistant cells.
Conclusions: Our results demonstrate an inverse correlation between the methylation level of TERT promoter and
ATRA efficacy in ovarian carcinoma cell lines. Although these results are preliminary, ATRA treatment could become
a new powerful, personalized therapy in serous ovarian carcinoma patients, but only in those with tumors
harboring a hypomethylated TERT promoter.
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Retinoids are a class of compounds that are structur-
ally associated to vitamin A. Experimental animal
models, cellular models, epidemiological data and
clinical trials provide a strong rationale for the use of
retinoids in cancer therapy and prevention [1]. All-
trans retinoic acid (ATRA) is the most abundant© The Author(s). 2019 Open Access This artic
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Full list of author information is available at the end of the articlenatural retinoid. The most effective clinical practice
in human disease was demonstrated in acute promye-
locytic leukemia where ATRA induces differentiation
of the leukemic promyelocytes into granulocytes [2,
3]. ATRA and other retinoids have also been found
to be effective in other hematological malignancies,
but also in the treatment or in clinical trials of sev-
eral types of solid cancers, such as thyroid [4], pros-
tate [5], and breast [6]. ATRA causes cell cycle arrest
at G1 phase and inhibits cell proliferation [2].
Although the mechanisms of the anti-cancer effects
of retinoids are not fully understood, it is likely thatle is distributed under the terms of the Creative Commons Attribution 4.0
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and induce apoptosis which may be a result of tel-
omerase inhibition [7–11].
The finding that most tumors express telomerase
activity has led to an exponential growth of research
to discover the role and regulation of this enzyme be-
cause the activation of telomerase is a critical step in
carcinogenesis and cellular immortalization [12, 13].
The main gene responsible of telomerase activity is
TERT (Telomerase Reverse Transcriptase). This gene
codes for the catalytic subunit of telomerase enzyme
liable to elongation of telomeres in up to 95% of ma-
lignant tumors [14]. TERT transcription leads to tel-
omerase activity, and is an important factor linked to
proliferation, differentiation and senescence. It is not
found in the majority of somatic cells, while it is
expressed in the proliferative cells such as germ cells,
stem cells, and in the majority of tumors [12, 15].
One of the possible adjustments of TERT is at its
promoter level. The TERT promoter is in a dense
CG-rich CpG-island, indicating a role for methylation
in the regulation of TERT expression [16]. TERT pro-
moter hypermethylation is very common in many
cancers contrarily to normal cells, and a positive cor-
relation was found between TERT methylation and
TERT expression, especially in epithelial tumors [17–
19]. The apparent opposition to the classic model of
regulation of gene expression by DNA methylation
was explained by the observation that methylation
plays a dual role for TERT promoter. TERT methyla-
tion prevents the binding and thus the repressive ef-
fect of CTCF, whereas a small hypomethylated region
around the transcription start site allows a weak tran-
scription of TERT, despite the hypermethylation of
the border regions [20, 21].
The study of Azouz et al. [22] demonstrated that
ATRA-inducible TERT repressors bind to the pro-
moter of TERT, only when this promoter is hypo-
methylated, blocking transcription of the gene and,
consequently, causing malfunction of telomerase. On
the one hand, TERT is generally hypomethylated in a
great majority of lymphoproliferative tumors [23]
where ATRA is effective, on the other hand, TERT is
hypermethylated in a majority of epithelial tumors
[18] where ATRA is generally ineffective. Ovarian car-
cinomas are heterogeneous tumors with different
morphological, molecular and clinical features and are
characterized by several aberrantly methylated genes,
among which TERT [24–28]. Nevertheless, we re-
cently found a hypomethylation of TERT promoter in
about one third of serous carcinomas [29], the most
lethal histotype of ovarian cancer.
Most of the advanced ovarian cancer patients respond
well to first line of chemotherapy based on carboplatinand taxane. Despite this high initial response rate, a ma-
jority of patients relapse and die of the disease [30]. The
response to second line of chemotherapy is much lower
[31]. To overcome resistance, it is important to search
for additional drugs that could be used in combination
to increase the anticancer effect.
The aim of this study was to predict the role of ATRA
as a potential anticancer drug in the sub-group of ovar-
ian carcinomas in which the TERT promoter is hypo-
methylated. Several ovarian carcinoma cell lines were
treated with ATRA, and we determined whether a cor-
relation between the antiproliferative and cytotoxic ef-
fects of all-trans retinoid acid and the methylation status
of TERT promoter in these cell lines exists.
Results
ATRA treatment and cellular growth
To evaluate the effective contribution of ATRA treat-
ment on cell growth in ovarian cancer cell lines, we
performed cell counts of control and treated cells on
days 3, 5 and 7 after treatment. The selected concen-
tration of 1 μM of ATRA was used for this study.
This concentration was chosen because it has been
shown the strongest support by patients according to
the pharmacokinetic studies, which permit to avoid
the severe toxicity of the drug [32]. The graphs of
cellular growth after ATRA treatment are shown in
Fig. 1. As a control (CTRL), we considered the cell
lines treated only with ethanol, the solvent for ATRA.
Together with ovarian carcinoma cell lines, we con-
sidered a colorectal carcinoma (CRC) cell line not
sensitive to 1 μM of ATRA, HT29 [33]. According to
the effect of ATRA on the last day of treatment (day
7), we highlighted three cell lines with an ATRA-
inhibitor effect on the cell growth.
The inhibitory action of ATRA on the cell growth was
a rapid and clearly marked process for the OVCAR3 cell
line (p<0.05). A substantial diminution of ATRA-treated
cell growth was observed on day 3, increasing up to day
7. PA1 and SKOV3 cells showed a cell growth dimin-
ution on day 7, whereas they did not show numeric dif-
ference on days 3 and 5. There were no changes in
growth curves between ATRA-treated and control cells
in any of the other ovarian cancer cell lines-A2780,
CAOV3, OVMZ6, OVMZ36, OVMZ37 and SKOV3-,
and in the HT29 CRC cell line.
ATRA treatment and cell viability
The effect of ATRA treatment on cell viability was
measured using the MTT colorimetric assay. The
ATRA-insensitive HT29 cells showed, as expected, a
cell viability almost unchanged. In regard to the ovar-
ian cells, the results of the MTT assay were in
complete agreement with those previously obtained
Fig. 1 Viable cell count of ovarian cancer cell lines. A) Days of treatment are reported on the x-axis and number of viable cells expressed in
percentage on the y-axis. Cells were grown only with ethanol (CTRL, ●) and in presence of 1 μM of ATRA (▲). HT29 cells, known to be resistant
to ATRA treatment, were used as a negative control. B) Histogram showing the cell number after 7 day of treatment respect to control. Each bar
represents the mean (±SD) of three independent experiments
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(OVCAR3, PA1 and SKOV3), we observed that the
percentage of viable cells decreased at the end of
ATRA treatment (p<0.05 for OVCAR3), (Fig. 2). In
OVCAR3, the percentage of cell viability decreased
significantly already from day 5 of treatment while for
the other two cells lines, the decrease in viability was
only observed on day 7. Concerning the other five
ovarian cell lines, no decrease in cell viability was no-
ticed. Surprisingly, we observed an increase in A2780
cell viability at the end of ATRA treatment.
ATRA treatment and TERT expression
TERT gene expression quantification was obtained with
real-time PCR on cDNA previously retro-transcripted.
Quantitative variation of TERT expression was per-
formed on cell samples collected on days 3 and 7 of
ATRA treatment. In ATRA treated cells, a decreased
TERT expression was noticed on day 7 at the end of
the treatment for OVCAR3, PA1, and SKOV3 (Fig. 3).
These 3 cell lines have already shown a decrease in
cell growth and cell viability after ATRA treatment.
In contrast, the other 5 ovarian cell lines and the
colon cell line, showed an increase in TERT expres-
sion after ATRA treatment.TERT promoter methylation
In order to evaluate the methylation level of TERT pro-
moter and search for a correlation with cell count, cell
viability, and TERT expression, we analyzed the pre-
treatment ovarian cell lines A2780, CAOV3, OVMZ6,
OVMZ36, OVMZ37, SKOV3, and HT29 CRC. Fig. 4 de-
picts the results of the pyrosequencing reporting the
percentage of methylation (part A) and their localization
(part B) for each of the 14 CpG sites analyzed. Signifi-
cant variability on methylation percentage for each CpG
site of the TERT promoter region was observed in all the
analyzed cell lines. According to the TERT methylation
status, we were able to identify 3 groups of cell lines.
OVCAR3 showed the lowest percentage of methyla-
tion among all the analyzed cell lines. The distribution
of methylation between the CpG sites varied from a
minimum of 13% to a maximum of 42%, with an average
DNA methylation level of 27%.
PA1 and SKOV3 cell lines showed an intermediate
level of methylation, especially for the first seven CpG
sites, with levels of methylation that varied between 44
and 70%, and an average methylation level of 55% for
PA1 and 59% for SKOV3; a unique peak of high methy-
lation, 65 and 70% for PA1 and SKOV3 was observed at
CpG position 10 (Fig. 4).
Fig. 2 Cell viability assay by MTT test in ovarian cancer cell lines. A) Days of treatment are shown on the x-axis and the percentage of viable cells
on the y-axis. Cell viability was determined in absence (CTRL, ●) and in presence of 1 μM of ATRA (▲). HT29 cells were used as a negative
control. B) Histogram showing cell survival (percentage) after 7 day of treatment respect to control. Each bar represents the mean (±SD) of three
independent experiments
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high methylation percentage that ranged from 72 to
100% in A2780, CAOV3, OVMZ6, OVMZ36 and
OVMZ37 with an average methylation level varying
from 83 to 92%. A high methylation level was observed
in the remaining seven CpG sites with percentage from
72 to 98% for A2780 and OVMZ37, while for CAOV3,
OVMZ6 and OVMZ36 levels of methylation were more
heterogeneous and ranged from a minimum of 51% to a
maximum of 99%.
TERT methylation level and response to ATRA
The average methylation level of the analyzed TERT
promoter region can be divided into 3 groups: low;
for an average methylation lower than 30%, inter-
mediate; for a methylation ranged from 30 to 70%,
and high; for a methylation up to 70%. Therefore,
TERT promoter methylation was low for OVCAR3,
intermediate for PA1 and SKOV3 and high for the
other cell lines.
ATRA treatment had an effect on cell growth, cell via-
bility, and TERT expression in the three ovarian cell
lines with a low or an intermediate level of TERT methy-
lation (Table 1). As it can be shown in Figs. 1, 2, and 3,
the effect of ATRA was more pronounced and occurredearlier in OVCAR3, the cell line with the lowest level of
TERT promoter methylation. By contrast, at the end of
ATRA treatment (day 7) no effect on the five ovarian
cell lines with a high level of TERT methylation was ob-
served (Table 1).
Discussion
In this study, we examined the effect of ATRA in
ovarian cancer cell lines in order to evaluate whether
epigenetic modification of TERT promoter gene can
be involved in different cellular response to retinoid
treatment. An inverse correlation between the level of
TERT promoter methylation and ATRA efficacy was
noticed. The serous ovarian carcinoma cell line
OVCAR3, which harbored a hypomethylated pro-
moter, was the strongest and fastest respondence to
ATRA treatment. The two cell lines with an inter-
mediate methylated promoter, PA1 and SKOV3, also
demonstrated a response though weaker and time de-
layed. On the contrary, the other ovarian cancer cell
lines showed a heavily methylated promoter and none
responded to ATRA.
Therefore, a strong correlation was observed be-
tween TERT promoter methylation levels and the re-
sults obtained by cell growth, cell viability, and TERT
Fig. 3 TERT expression by real time PCR in ovarian cancer and HT29 cell lines. Days of treatment are shown on the x-axis and TERT expression on
the y-axis. TERT expression was determined in absence (red bars; CTRL) and in presence (blue bars) of 1 μM ATRA. The last cell line HT29 was used
as a negative control. Each bar represents the mean (±SD) of three independent experiments
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promoter methylation allow an ATRA inhibitory ac-
tion on TERT expression and cell growth, as observed
in the serous ovarian carcinoma cell line OVCAR3.
Although the mechanisms of the anti-cancer effects
of retinoids are not fully understood, it is likely that
they are due to the ability to inhibit cell proliferation
and induce apoptosis, which may be a result of tel-
omerase inhibition [7–11, 34]. Indeed, this mechanism
was proposed by Love et al., 2008 in human leukemia
cells in which ATRA treatment reduced cellular pro-
liferation and induced apoptosis in the HL60 cells,
only after inhibition of telomerase activity due to the
down-regulation of TERT transcription [9]. The au-
thors proposed that the epigenetic changes in the
TERT promoter represent a stable locking mechanism
in the retinoid-induced suppression of telomerase ac-
tivity. Later, the study of Azouz et al. demonstrated
in acute promielocytic leukemia cell line that ATRA-
inducible TERT repressors bind to the promoter of
TERT when it is not methylated, blocking transcrip-
tion of the gene and, consequently, causing malfunc-
tion of telomerase [22].
Most ovarian cancer cells are sensitive to platinum,
which is especially the case of the four cell linesinvestigated in this study, A2780, CAOV3, SKOV3
and OVCAR3 [35, 36]. However, these four cell lines
revealed different responses to ATRA and varying
levels of TERT promoter methylation. Therefore, we
can conclude that there are no correlations between
sensitivity to platinum, ATRA response, and the sta-
tus of TERT promoter methylation in ovarian cancer
cell lines.
Our results are in agreement with previous findings
obtained in leukemia cell lines suggesting that epigen-
etic mechanism can be responsible of different ATRA
response and highlights that a low methylation level
of TERT promoter correlates with drug efficacy. By
contrast, the drug was not active in cell lines with a
high hypermethylation of TERT. Furthermore, our
data confirms that telomerase activity, through TERT
promoter methylation, plays an important role in cell
immortalization and continues to be subject for fu-
ture studies and applications in molecular therapies.
In a parallel project, we analyzed neoplastic tissue of
serous ovarian carcinoma patients and observed TERT
promoter hypomethylation in about one third of cases
[29]. For this reason, we expected to find more cell
lines with low methylation levels, not only one. More-
over, CAOV3 cell line, differently from us, was found
Fig. 4 TERT promoter methylation in ovarian cell lines. (a) Methylation level at each CpG site of TERT promoter by pyrosequencing of ovarian
cancer and HT29 cell lines. (b) The analyzed 14 CpG sites of the 127 bp amplified region of TERT promoter (NCBI Reference Sequence:
NG_009265.1). This region is situated 273–400 bp upstream the ATG translation start site
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the same group [37, 38]. As already well described,
an explanation can be due to the changes that occur
during the culture of cells prolonged for a long time
[39, 40]; specific clones characterized by higher
methylation level can be selected. Wu et al. (1997),
showed different responsiveness from clone to clone
[37]. On the other hand, we tried to use different cell
lines without TERT methylation, but had severalTable 1 Correlation between level of TERT promoter methylation




Cellular growth Cell viability TERT expression
OVCAR3 Low ↘ ↘ ↘
PAI1 Intermediate ↘ ↘ ↘
SKOV3 Intermediate ↘ ↘ ↘
A2780 High → → ↗
CAOV3 High → → ↗
OVMZ6 High → → ↗
OVMZ36 High → → ↗
OVMZ37 High → → ↗difficulties with their culture because they were in-
clined to differentiate and die off quickly.Conclusions
Our study demonstrated the importance of TERT epi-
genetic modification in the cellular response of retinoid
treatment in ovarian cancer cell lines. A hypomethyla-
tion of the TERT promoter, even partial, will lead to a
response to ATRA treatment, whereas a complete hyper-
methylation will lead to a total absence of ATRA effi-
cacy. If confirmed by further biological and clinical
studies, ATRA could be used in combination with plat-
inum therapy in patients with TERT hypomethylated
ovarian carcinomas, representing a further example of
precision medicine.Materials and methods
Cell culture
Human serous ovarian carcinoma cell lines (A2780,
CAOV3, OVCAR3, OVMZ6, OVMZ36, OVMZ37,
SKOV3), ovarian teratocarcinoma cell line (PA1) and hu-
man colorectal carcinoma (CRC) cell line HT29 were ob-
tained from the Department of Molecular Pathology










































































































































































































































Losi et al. Journal of Ovarian Research           (2019) 12:62 Page 7 of 10
Losi et al. Journal of Ovarian Research           (2019) 12:62 Page 8 of 10and OVCAR3 were reported to be sensitive to very sensi-
tive to platinum based chemotherapy [35].
Cells were cultured in Roswell Park Memorial Insti-
tute Medium (RPMI 1640) + L-glutamine supplemented
with 10% Fetal Bovine Serum (FBS), 1% PSF (Penicillin/
streptomycin + Fungizone - Amphotericin B) and in
Dulbecco’s Modified Eagle Medium + 4.5 g/l D-glucose
+ Pyruvate (DMEM), supplemented with 10% Fetal Bo-
vine Serum (FBS), 1% PSF. Cells were maintained in a
humidified atmosphere at 37 °C and in 5% CO2. Cell
lines were stored in liquid nitrogen with 5% DMSO. All
products were from ThermoFisher Scientific. All cell
lines tested negative for mycoplasma contamination
using MycoAlertTM Mycoplasma Detection Kit, Lonza,
catalog number LT07–318.
ATRA treatment
All-Trans Retinoic Acid (ATRA) powder was purchased
from Sigma Aldrich. ATRA was dissolved in ethanol at
final concentration of 5mM and stored at − 20 °C. 2 × 105
cells were seeded in six well plates. After 24 h, the cells
were treated for 7 days with medium containing ATRA
with a final concentration of 1 μM. Cell medium was re-
placed every 48 h. Cells were collected on day 3, 5 and 7
after ATRA treatment, counted using a Neubauer hema-
tocytometer, and cell pellets were frozen for subsequent
analyses. As a control, we used cell lines treated only with
ethanol, the solvent for ATRA. Experiments were per-
formed in triplicate.
Cell viability assay
Cell viability was measured using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Alfa Aesar). Cells were plated in 96-well plates
and treated with ATRA as described above. After in-
cubation for the indicated time intervals, 0.5 mg/mL
of MTT was added to each well for 4 h. The blue
MTT formazan precipitate was then dissolved in
200 μL of an Isopropanol-HCl solution. The absorb-
ance at 540 nm was measured by Synergy™Mx spec-
trophotometer (BioTek). Gen5™ software (BioTek) was
used for the analysis.
Real-time PCR evaluation of TERT mRNA
RNA extraction was performed by using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions.
Subsequently, the reverse transcription-polymerase chain
reaction (RT-PCR) was performed with 2 μg of total RNA
using SuperScript™ III Reverse Transcriptase (Thermo-
Fisher Scientific). The profile used for the reaction was:
25 °C for 5min, 50 °C for 50min and 70 °C for 15min.
Next, the real-time PCR was performed with 2 μL of
cDNA using a Platinum® Taq DNA polymerase (Thermo-
Fisher Scientific) and a mix of TERT and GAPDH primers(Table 2). Samples were amplified by 45 cycles at 95 °C for
10 s, 58 °C for 10 s, and 72 °C for 15 s, in a Rotor-Gene
6000 and data were analyzed with Rotor-Gene Q Series
Software (Qiagen). For each sample, three replicates were
acquired. TERT mRNA expression was normalized with
GAPDH as an internal control.
TERT methylation analysis by bisulfite pyrosequencing
DNA was extracted from cell lines using DNeasy
Blood & Tissue Kit as descripted by the manufacturer
(Qiagen). Extracted DNAs (500 ng) were bisulfite
modified using EpiTect Fast DNA kit according to
the manufacturer’s protocol (Qiagen). Briefly, a total
of DNA was denaturated with sodium hydroxide and
modified with sodium bisulfite. DNA samples were
then purified using MiniElute DNA spin columns and
elution of converted DNA was performed with 20 μL
elution buffer.
The eluted, bisulfite converted DNA was used for
pyrosequencing PCR amplification. Bisulfite-PCR-
Pyrosequencing was performed in 20 μL reaction mix-
ture containing 3 μL of converted DNA and forward
and biotinylated reverse primers (TERT-pyr-Fwd and
TERT-pyr-Rev, Table 2). The PCR conditions were as
follows: after an initial 5-min denaturation step at
95 °C, 40 amplification cycles were performed, each
consisting of denaturation (15 s at 95 °C), annealing
(15 s at 60 °C) and elongation (30 s at 72 °C) steps
followed by a final incubation at 72 °C for 5 min. The
expected PCR product size was 127 bp. Ten μL of bi-
otinylated PCR product was immortalized on
streptavidin-coated sepharose high-performance beads
(GE Healthcare Bio-sciences AB) and processed to
obtain a single-strand DNA using the PyroMark Vac-
uum Prep Workstation (Qiagen) according to the
manufacturer’s instruction. The template was incu-
bated with 3 μmol/L TERT-pyr-Seq sequencing primer
at 80 °C for 2 min. The pyrosequencing reaction of
the complementary strand was automatically per-
formed on PyroMark Q24 Advanced (Qiagen) using
PyroGold reagents (Qiagen). As nucleotides were dis-
pensed, a light signal was generated proportional to
the amount of each incorporated nucleotide. The per-
centage of cytosine methylation for each CpG site
within the analyzed region of the TERT promoter
gene was calculated using the PyroMark Q24 Soft-
ware (Qiagen) that allows the methylation analysis at
each CpG site.
Statistical analysis
All assays were performed at least three times. The re-
sults were presented as mean ± SD. Statistical analysis
was conducted by t-test. P < 0.05 was considered
significant.
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